The SELECT trial (published in NEJM 2023) established semaglutide's cardiovascular benefits in patients with established cardiovascular disease and overweight or obesity but without diabetes
Furthermore, limited diagnostic capabilities, difficulty in identifying eligible patients, and variability in disease progression collectively contribute to low enrollment rates, prolonged study timelines, and compromised data integrity in rare disease trials, ultimately resulting in higher failure rates compared to non-rare disease trials 5,6
Learn about peptide combinations , cycling strategies , stacking protocols , and complementary ingredients
At this stage in her career, Marian is a perfect fit for Vida at this point as our company continues to grow and introduce innovations to health and beauty, concludes Armigos